No membership fee required. No yearly fees. Only pay for what you want. Cancel anytime.

Apexion Health Tesamorelin treatment vial
WEIGHT LOSSGHRH

MONTHLY SUPPLY · INJECTION

TESAMORELIN

TREATMENT

Growth hormone-releasing factor analog that selectively reduces visceral adipose tissue while preserving lean body mass.

SUPPORT

Tesamorelin is a synthetic form of growth hormone-releasing hormone (GHRH) that stimulates the pituitary to produce and release growth hormone. It has been specifically shown to reduce visceral adipose tissue (fat around internal organs) while preserving lean body mass, making it unique among weight-management peptides.

Shop Now

Lab-Tested · Physician-Supervised · Discreet Delivery

Apexion Health — WEIGHT LOSS

TARGETED FAT LOSS. LEAN MASS PRESERVED.

Unlike general growth hormone stimulation which can affect fat distribution throughout the body, tesamorelin has demonstrated a specific affinity for reducing visceral adipose tissue — the metabolically active fat that surrounds internal organs and is strongly associated with cardiovascular risk and metabolic dysfunction. This targeted effect makes it particularly valuable for patients with abdominal obesity who wish to improve their metabolic profile without losing hard-earned muscle mass.

Clinical Benefits

TESAMORELIN SUPPORTS YOUR HEALTH AT THE CELLULAR LEVEL

  1. 01.

    SELECTIVELY REDUCES VISCERAL ADIPOSE TISSUE

  2. 02.

    PRESERVES LEAN BODY MASS DURING FAT LOSS

  3. 03.

    STIMULATES PITUITARY TO PRODUCE GROWTH HORMONE

  4. 04.

    IMPROVES METABOLIC MARKERS ASSOCIATED WITH ABDOMINAL OBESITY

  5. 05.

    PHYSICIAN-SUPERVISED WITH REGULAR HORMONE MONITORING

Shop Now

Clinical Evidence

How It Works in the Body

01 — Dose & Efficacy

Visceral Adipose Tissue Reduction

VAT Reduction (26 wks) −15.4% vs placebo in pivotal trials45%
IGF-1 Increase +81% — confirming GH axis activation81%
Trunk Fat Reduction −6.3% from baseline (pooled data)35%

Falutz et al., NEJM 2007; Falutz et al., JCEM 2010 (Phase III)

02 — Hormone Panel

Body Composition & Metabolic Changes (Phase III)

MarkerWithoutWith Treatment
Visceral Adipose Tissuecm²
179
151−28 (−15.4%)
IGF-1ng/mL
180
326+146 (+81%)
Trunk Fatkg
14.8
13.9−0.9 (−6.3%)
Total Cholesterolmg/dL
197
193−4 (ns)

FDA-approved for HIV-associated lipodystrophy — strong clinical data

Tesamorelin is the only FDA-approved therapy specifically for VAT reduction. Two Phase III RCTs (n=816) confirmed −15.4% VAT vs placebo at 26 weeks. Effect reverses upon discontinuation — sustained therapy required.

Falutz et al., NEJM 2007; Falutz et al., JCEM 2010

03 — Protocol

Tesamorelin Treatment Protocol

BaselinePre-treatment
  • ›DEXA or CT for VAT quantification
  • ›IGF-1, metabolic panel, HbA1c
  • ›Waist circumference & weight
Active TreatmentMonths 1–6
  • ›Tesamorelin 2 mg SC daily
  • ›IGF-1 at months 1 & 3
  • ›Waist circumference monthly
  • ›VAT recheck at 6 months
ContinuationMonth 6+
  • ›VAT confirmed reduction at 6 months
  • ›Continue if benefit demonstrated
  • ›IGF-1 & metabolic q6 months

2 mg SC daily — effects reverse upon discontinuation

VAT reduction plateaus at ~6 months; ongoing treatment maintains the effect. Discontinuation known to result in VAT regain. Common side effects: injection site reactions, arthralgia, transient edema. Contraindicated in active malignancy.

All protocols physician-supervised and adjusted per individual labs.